- Conditions
- Obesity, Overweight
- Interventions
- Cagrilintide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Walnut Creek, California • Aurora, Colorado • Orlando, Florida + 6 more
Location Directory
Clinical trials in Denver, Colorado
This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7463
Shown on this page
12
Current sort
Recently updated
Location scope
Denver, CO
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 997–1008 of 7,463 matching trials in Denver, CO.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Myeloproliferative Neoplasms
- Interventions
- INCA035784
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Palo Alto, California • Denver, Colorado + 9 more
- Conditions
- Persistent Atrial Fibrillation
- Interventions
- Adagio AF Cryoablation System (iCLAS™)
- Device
- Lead sponsor
- Adagio Medical
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 13 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PLN-74809, Placebo
- Drug
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
- Conditions
- Cancer, Metastatic Cancer
- Interventions
- Blood Testing
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- GA Depot, Placebo
- Drug · Other
- Lead sponsor
- Mapi Pharma Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Interventions
- Pembrolizumab, Patient Observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
- Biological · Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 828
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 600 more
- Conditions
- Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
- Interventions
- Apraglutide, Placebo
- Drug
- Lead sponsor
- VectivBio AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
- Conditions
- Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 488
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
- Conditions
- Cancer
- Interventions
- SynKIR-110, SynKIR-310
- Drug
- Lead sponsor
- Verismo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Atlanta, Georgia • Westwood, Kansas + 4 more
- Conditions
- Multiple Sclerosis, Myasthenia Gravis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
- Conditions
- Lupus Erythematosus, Systemic, Lupus Nephritis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 28 more